Curis to Release Fourth Quarter 2022 Financial Results and Hold Conference Call on March 9, 2023

Curis, Inc. (NASDAQ: CRIS) announces it will release its fourth quarter 2022 financial results on March 9, 2023, following the close of U.S. markets.

Rhea-AI Summary

Curis, Inc. (NASDAQ: CRIS) announces it will release its fourth quarter 2022 financial results on March 9, 2023, following the close of U.S. markets. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss the results. Curis focuses on developing innovative cancer therapeutics and has ongoing collaborations with Aurigene, ImmuNext, and Genentech. Notably, the FDA has placed a partial clinical hold on Curis's TakeAim Leukemia trial, affecting patient enrollment for some phases. For more details, visit Curis's website.

Positive

• Collaboration with Aurigene for immuno-oncology and precision oncology.
• Emavusertib is in clinical trials for hematologic malignancies with Orphan Drug Designation.

Negative

• Partial clinical hold on the TakeAim Leukemia trial affecting new patient enrollment.

Argus Session date unavailable

+8.32% session move Open Argus

Details

News Market Reaction – CRIS

The recorded move for CRIS in the trading session of this news was +8.32%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass., March 2, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter 2022 financial results on Thursday, March 9, 2023, after the close of U.S. markets. Management will host a conference call on the same day at 4:30 p.m. ET.

To access the live conference call, please dial (888)-346-6389 from the United States or (412)-317-5252 from other locations, shortly before 4:30 p.m. ET. The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section. A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.

About Curis, Inc.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, emavusertib (CA-4948). Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma trial in patients with hematologic malignancies, such as non-Hodgkin's lymphoma and other B cell malignancies, both as a monotherapy and in combination with BTK inhibitor ibrutinib, and the Phase 1/2 TakeAim Leukemia trial in patients with acute myeloid leukemia and myelodysplastic syndrome, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. The FDA has placed a partial clinical hold on the TakeAim Leukemia trial during which no new patients will be enrolled in the monotherapy expansion phase (Phase 2a) or the combination phase (Phase 1b) of emavusertib with azacitidine or venetoclax. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-release-fourth-quarter-2022-financial-results-and-hold-conference-call-on-march-9-2023-301761550.html

SOURCE Curis, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Curis release its fourth quarter 2022 financial results?

Curis will release its fourth quarter 2022 financial results on March 9, 2023.

What time is the Curis conference call scheduled for?

The Curis conference call is scheduled for 4:30 p.m. ET on March 9, 2023.

What is the significance of the FDA's partial clinical hold on Curis's trials?

The partial clinical hold restricts new patient enrollment in the TakeAim Leukemia trial, impacting ongoing research efforts.

What collaborations does Curis have in cancer treatment development?

Curis has collaborations with Aurigene, ImmuNext, and Genentech for the development of cancer therapeutics.